Trial Profile
A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 27 Sep 2017 Results of 24-month sub-analysis from this trial, presented at the 18th Congress of the European Society for Organ Transplantation.
- 27 Sep 2017 Results of a subanalysis comparing the efficacy and safety of everolimus+reduced-dose cyclosporine (EVR+rCsA) vs mycophenolate mofetil+standard-dose cyclosporine (MMF+sCsA) regimens in a subpopulation of KTR with ≥3 HLA mismatches, presented at the 18th Congress of the European Society for Organ Transplantation
- 03 May 2017 Results of subgroup analysis assessing renal function outcome in HLA mismatch groups (n=100) presented at the 2017 American Transplant Congress